Anderson C, et al. - In a prospective cohort of women with a first-degree family history of breast cancer (The Sister Study), researchers characterized the risk-benefit profiles for chemoprevention with tamoxifen or raloxifene. Post-exclusion, they matched—on age and year of cohort enrollment—432 current raloxifene users and 96 current tamoxifen users to 4,307 and 953 non-users, respectively. As prophylaxis against breast cancer, raloxifene vs tamoxifen was more commonly used. The likelihood of a benefit was reported in most raloxifene users but in < 60% of tamoxifen users. In order to make an informed decision regarding breast cancer chemoprevention, the use of risk-benefit tables can offer assistance, according to the investigators.